Cytokinetics (CYTK) stock
CYTK's Quality Score fell 1 point on Mon, Nov 2, to -4. It did not trade higher than the day before.
Follow CYTK's trial news. Pro members can get an alert when Cytokinetics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Key facts on CYTK
| Since its 2024 high | Down 42% |
| Latest filing | 10-Q, Aug 6 |
CYTK in the news
ReportReports Wednesday, after the close. Every 3 months, a company tells everyone how much it sold and earned. It fell after 3 of its last 4 reports, -4.2% on average. Past reports ›
What's next
Fri Nov 6: Hypertrophic Cardiomyopathy Medical…Industry event · date confirmed.
CYTK catalysts
After its last 4 reports it closed -4.3% on average, higher 1 of 4 times.
What's next for CYTK, and how long its cash lasts
Next step the company has named
Cash runway
About 12 quarters
Dilution on the horizon
- Shelf registration (S-3ASR, filed Feb 27, 2025)
- At-the-market share sales program (S-3ASR, filed Feb 27, 2025)
Insiders
An officer, Fady Ibraham Malik, sold 3,500 shares on Oct 20, under a planned sale. 62 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
- In 20 days
CAPRCapricor Therapeutics
- In 20 days
SVRASavara
- In 50 days
MLYSMineralys Therapeutics
Why CYTK scores -4
Poorfor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means
- +2Chart checks 2 of 14 firing right now, one point each
- −2Growth sales down 21% on the year, operating margin down 408.2 points
- Long-term trend subtracts
- Profit subtracts
- Dilution subtracts
- Cash flow subtracts
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
CYTK has 2 of 14 chart checks firing
CYTK RSI today: 42.7, below its 50-day and 200-day averages
- RSI 1442.7
- MACD (12, 26, 9)Above signal
- 50-day average$67.20
- 200-day average$70.07
- 50/200 crossDeath cross
- ADX 1423.5
- Support$60.05
- Resistance$64.68
- 52-week high$88.31
- 52-week low$58.05
- Chart patternNone
- Bollinger Bands (20, 2)Inside
- Volume0.9x
The deep dive on CYTK
- What it does and how it makes moneySEC filing · Feb 26, 2026SEC filing · Feb 26, 2026SEC filing · Feb 26, 2026
- Where it stands
- What changed in its filingsSEC filing · Aug 6, 2026
- Who holds and trades it
- Against its closest peers
How CYTK ranks in Pharma
CYTK is #71 of 92 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 71 |
Net income over four quarters: CYTK -$894M, DYN -$519M.
When does CYTK report earnings, and what happens after?
Reports Wed Nov 4, after the close (in 2 days). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
What CYTK reported on Aug 6, 2026
The quarter
The figures are not read from the release yet.
“The decrease was primarily due to higher clinical trial activity, supply chain costs, and medical affairs activities in 2025 partially offset by higher personnel-related costs in 2026.”
Where the sales came from
CYTK's results filing gives no sales by line in a table we read.
The outlook
No outlook figures read from this release.
In the company's words
“The increase was primarily due to costs associated with the commercial launch of MYQORZO and higher personnel-related costs, including stock-based compensation.”
From its results filing (SEC filing · Aug 6)
The numbers
- $8.8B
- today
- $67.7M
- down 21.1% on the year
- -$581M
- last 12 months
Sales grew 9.5% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 13% a year over 5 years.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 6, 2026 | -0.2% | -5.7% | -9.7% |
| May 5, 2026 | +1.7% | -2.9% | -3.0% |
| Feb 24, 2026 | -2.8% | -10.3% | -13.4% |
CYTK sales and profit by year
Sales grew in five of the last seven years, to $88M in 2025. It lost money in each of the eight years.
Insiders trading CYTK
CYTK trades by Congress and the executive branch
2 trades disclosed in the last six months. The newest:
CYTK's officers and directors
Officers and directors with a Form 4 in the last 12 months.
Which ETFs hold CYTK?
In ETFs: CYTK is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
About Cytokinetics
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
What Cytokinetics says it competes with
“Our competitors and potential competitors include major pharmaceutical and biotechnology companies, as well as academic research institutions, clinical reference laboratories and government agencies that are pursuing research activities similar to ours.”
CYTK's score card
Pro members see every line of every stock's score.
- What would turn CYTK's score around: 8 things
- 4 more filings explained, a plain line each
- Real-time prices, no delay
Straight Answers
Is CYTK a good stock to buy? What its Quality Score says
CYTK scores -4 today, which Breakaway calls Poor. It is #71 of 92 in Pharma by Quality Score, with 2 of 14 chart checks firing. Cash lasts about 12 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
What is CYTK's Quality Score?
CYTK scores -4 today, which Breakaway calls Poor (below zero). That is #71 of 92 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind CYTK's -4.
When does CYTK report earnings?
Reports Wed Nov 4, after the close, a date the company confirmed. CYTK closed higher after 1 of its last 4 reports. Past behavior, not a forecast.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.